|
|||||
|
|
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy |
|
| Authors: | Jinge Zhao Mengni Zhang Jiandong Liu Zhenhua Liu Pengfei Shen Ling Nie Wenhao Guo Diming Cai Jiyan Liu Cameron M. Armstrong Guangxi Sun Junru Chen Sha Zhu Jindong Dai Haoran Zhang Peng Zhao Xingming Zhang Xiaoxue Yin Xudong Zhu Yuchao Ni Ni Chen Hao Zeng |
| Affiliation: | 1. Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China Jinge Zhao, Mengni Zhang, Jiandong Liu, Zhenhua Liu, and Pengfei Shen are the co-first authors and contributed equally to this study.;2. Department of Pathology, West China Hospital, Sichuan University, Chengdu, China Jinge Zhao, Mengni Zhang, Jiandong Liu, Zhenhua Liu, and Pengfei Shen are the co-first authors and contributed equally to this study.;3. Department of Pathology, West China Hospital, Sichuan University, Chengdu, China;4. Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, China;5. Department of Ultrasound, West China Hospital, Sichuan University, Chengdu, China;6. Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China;7. Department of Urology and Comprehensive Cancer Center, University of California Davis, Sacramento, California;8. Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China |
| Abstract: | |
| Keywords: | abiraterone AKR1C3 docetaxel mCRPC prostate rebiopsy |